Clinical Trial

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Participants in this study will be given either CDI-988 or placebo orally before receiving a norovirus challenge virus and continuing for 5 days. Participants will not know whether they are getting placebo or CDI-988. The study will evaluate how well CDI-988 compared to placebo can reduce the incidence of clinical symptoms after a challenge with norovirus. The amount of virus in stool samples will be measured over time. Side effects and pharmacokinetics (the amount of CDI-988 in blood) will also be measured.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-25; most recent amendment 2026-02-12.
Status change: Not Yet Recruiting → Recruiting 2026-02-12
Trial Details
NCT Number NCT07198139
Lead Sponsor Cocrystal Pharma, Inc.
Conditions Norovirus
Enrollment 40 participants
Start Date 2026-03-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17